SCHEMBL4290220

SCHEMBL4290220

COCCCC[C@@](O)(c1ccccc1Oc1ccccc1)C1CCCN(C(=O)N2CCCC(N)C2)C1

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
REN P00797 20/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290217 1.00 REN (0.77) REN
SCHEMBL4301219 0.97 REN (0.76) REN
SCHEMBL4301222 0.97 REN (0.76) REN
SCHEMBL4295207 0.92 REN (0.68) REN
SCHEMBL4297378 0.92 REN (0.68) REN
SCHEMBL4295201 0.92 REN (0.68) REN
SCHEMBL5513588 0.91 REN (0.78) REN
SCHEMBL4294587 0.90 REN (0.66) REN
SCHEMBL4294581 0.90 REN (0.66) REN
SCHEMBL1867948 0.90 REN (0.79) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 REN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.